PL3484446T3 - Kompozycje przeciwciał - Google Patents
Kompozycje przeciwciałInfo
- Publication number
- PL3484446T3 PL3484446T3 PL17745672.0T PL17745672T PL3484446T3 PL 3484446 T3 PL3484446 T3 PL 3484446T3 PL 17745672 T PL17745672 T PL 17745672T PL 3484446 T3 PL3484446 T3 PL 3484446T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody compositions
- antibody
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612317.6A GB201612317D0 (en) | 2016-07-15 | 2016-07-15 | Antibody compositions |
| PCT/EP2017/067870 WO2018011404A1 (en) | 2016-07-15 | 2017-07-14 | Antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3484446T3 true PL3484446T3 (pl) | 2025-02-24 |
Family
ID=56890667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17745672.0T PL3484446T3 (pl) | 2016-07-15 | 2017-07-14 | Kompozycje przeciwciał |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11351257B2 (pl) |
| EP (2) | EP3484446B1 (pl) |
| DK (1) | DK3484446T3 (pl) |
| ES (1) | ES2993464T3 (pl) |
| FI (1) | FI3484446T3 (pl) |
| GB (1) | GB201612317D0 (pl) |
| HR (1) | HRP20241637T1 (pl) |
| HU (1) | HUE069391T2 (pl) |
| LT (1) | LT3484446T (pl) |
| PL (1) | PL3484446T3 (pl) |
| PT (1) | PT3484446T (pl) |
| RS (1) | RS66141B1 (pl) |
| SI (1) | SI3484446T1 (pl) |
| SM (1) | SMT202500088T1 (pl) |
| WO (1) | WO2018011404A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017014684A2 (en) | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| JP7438396B2 (ja) * | 2020-04-14 | 2024-02-26 | フィロジェン ソチエタ ペル アツィオーニ | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
| US11872288B2 (en) | 2020-05-22 | 2024-01-16 | Philogen S.P.A. | TNF-alpha immunoconjugate therapy for the treatment of brain tumors |
| WO2023180341A1 (en) | 2022-03-21 | 2023-09-28 | Philogen S.P.A | TNFα IMMUNOCONJUGATE PREPARATION |
| JP2025510708A (ja) | 2022-03-23 | 2025-04-15 | ピロゲン エス．ピー．エー | Ｉｌ２免疫複合体調製物 |
| CA3265831A1 (en) * | 2022-09-01 | 2024-03-07 | Philogen Spa | TNF ALPHA AND INTERLEUKIN-2 POLYTHERAPY FOR THE TREATMENT OF NON-MELANOMA SKIN CANCER |
| WO2025172582A1 (en) * | 2024-02-15 | 2025-08-21 | Philogen S.P.A | Methods for treating melanoma |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| CA2399866C (en) | 2000-02-24 | 2011-05-10 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| SI2944306T1 (sl) * | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
| CA2849033C (en) | 2011-09-26 | 2020-05-05 | Philogen S.P.A. | Immunocytokine combination therapy |
| JP2016518386A (ja) * | 2013-05-02 | 2016-06-23 | マブキシェンス エス．アー． | ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物 |
| SG11201607306PA (en) | 2014-04-07 | 2016-09-29 | Seattle Genetics Inc | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| SG11201607258SA (en) * | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
-
2016
- 2016-07-15 GB GBGB1612317.6A patent/GB201612317D0/en not_active Ceased
-
2017
- 2017-07-14 PT PT177456720T patent/PT3484446T/pt unknown
- 2017-07-14 DK DK17745672.0T patent/DK3484446T3/da active
- 2017-07-14 HU HUE17745672A patent/HUE069391T2/hu unknown
- 2017-07-14 SI SI201731562T patent/SI3484446T1/sl unknown
- 2017-07-14 LT LTEPPCT/EP2017/067870T patent/LT3484446T/lt unknown
- 2017-07-14 HR HRP20241637TT patent/HRP20241637T1/hr unknown
- 2017-07-14 SM SM20250088T patent/SMT202500088T1/it unknown
- 2017-07-14 PL PL17745672.0T patent/PL3484446T3/pl unknown
- 2017-07-14 US US16/317,902 patent/US11351257B2/en active Active
- 2017-07-14 EP EP17745672.0A patent/EP3484446B1/en active Active
- 2017-07-14 RS RS20241219A patent/RS66141B1/sr unknown
- 2017-07-14 FI FIEP17745672.0T patent/FI3484446T3/fi active
- 2017-07-14 WO PCT/EP2017/067870 patent/WO2018011404A1/en not_active Ceased
- 2017-07-14 ES ES17745672T patent/ES2993464T3/es active Active
- 2017-07-14 EP EP23169312.8A patent/EP4233843A3/en active Pending
-
2022
- 2022-05-25 US US17/824,482 patent/US12023381B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3484446A1 (en) | 2019-05-22 |
| US11351257B2 (en) | 2022-06-07 |
| US20210093720A1 (en) | 2021-04-01 |
| EP3484446B1 (en) | 2024-09-25 |
| SMT202500088T1 (it) | 2025-03-12 |
| PT3484446T (pt) | 2024-11-21 |
| US20230165960A1 (en) | 2023-06-01 |
| US12023381B2 (en) | 2024-07-02 |
| FI3484446T3 (fi) | 2024-11-21 |
| DK3484446T3 (da) | 2024-11-04 |
| ES2993464T3 (en) | 2024-12-30 |
| GB201612317D0 (en) | 2016-08-31 |
| EP4233843A3 (en) | 2023-09-27 |
| SI3484446T1 (sl) | 2025-01-31 |
| LT3484446T (lt) | 2024-11-25 |
| WO2018011404A1 (en) | 2018-01-18 |
| RS66141B1 (sr) | 2024-12-31 |
| HRP20241637T1 (hr) | 2025-02-14 |
| EP4233843A2 (en) | 2023-08-30 |
| HUE069391T2 (hu) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265844A (en) | Anti-lag-3 antibodies and preparations | |
| IL262176A (en) | Anti-tim-3 antibodies and preparations | |
| IL261792B (en) | Preparations | |
| IL251282A0 (en) | Preparations containing anti-il-7r antibody | |
| IL260933A (en) | Preparations containing tocorsol or its analogues | |
| HUE069391T2 (hu) | Antitest kompozíciók | |
| GB201610156D0 (en) | Cliptac compositions | |
| GB201600075D0 (en) | Immunogenci composition | |
| IL260083B1 (en) | Antibody against myl9 | |
| GB201622161D0 (en) | Compositions | |
| GB201614799D0 (en) | Compositions | |
| GB201612658D0 (en) | Composition | |
| GB201611782D0 (en) | Composition | |
| GB201612359D0 (en) | Composition | |
| GB201602658D0 (en) | Compositions | |
| GB201607924D0 (en) | Composition | |
| GB201614230D0 (en) | Compositions | |
| GB201611960D0 (en) | Compositions | |
| GB201611851D0 (en) | Compositions | |
| GB201616785D0 (en) | Composition | |
| GB201614231D0 (en) | Composition | |
| GB201613992D0 (en) | Composition | |
| GB201602656D0 (en) | Compositions | |
| GB201610688D0 (en) | Composition | |
| GB201610707D0 (en) | Composition |